Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world.
Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer
Pfizer’s forecast for sales of its COVID-19 vaccine and treatment next year falls more than $5 billion short of the Wall Street consensus.
Company bosses and workers grapple with the fallout of speaking up about the Israel-Hamas war
The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard.
In venue fit for head of state, Japan PM seeks Pfizer doses
Japan’s prime minister met with Pfizer’s CEO in an unusually high-profile setting to make sure the drugmaker would deliver COVID-19 vaccine it has promised to the nation.
Biden mourns 500,000 dead, balancing nation's grief and hope
I know what it’s like to not be there when it happens," said Biden, who has long addressed grief more powerfully than perhaps any other American public figure. "I know what it’s like when you are there, holding their hands, as they look in your eye and they slip away. In one of his many symbolic breaks with his predecessor, Biden has not shied away from offering remembrances for the lives lost to the virus. The COVID-19 death total in the United States had just crossed 400,000 when Biden took the oath of office. Outside of perfunctory tweets marking the milestones of 100,000 and 200,000 deaths, Trump oversaw no moment of national mourning, no memorial service.
Britain OKs Pfizer vaccine and will begin shots within days
In giving the go-ahead for emergency use of the vaccine developed by American drugmaker Pfizer and Germany’s BioNTech, Britain vaulted past the United States by at least a week. Other countries aren’t far behind: Regulators in not only the U.S. but the European Union and Canada also are vetting the Pfizer vaccine along with a shot made by Moderna. Hancock said Britain will begin receiving the first shipment of 800,000 doses from Belgium within days, and people will start getting the shots as soon as it arrives. Still to be determined is whether the Pfizer-BioNTech shots prevent people from spreading the virus when they have no symptoms. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.
Pfizer says COVID-19 vaccine is looking 90% effective
On Monday, Nov. 9, 2020, Pfizer said an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19. Pfizer released no specific breakdowns, but for the vaccine to be 90% effective, nearly all the infections must have occurred in placebo recipients. The study is continuing, and Pfizer cautioned that the protection rate might change as more COVID-19 cases are added to the calculations. REPORT 90% EFFECTIVE. Earlier this year, Fauci said he would be happy with a COVID-19 vaccine that was 60% effective.
Pfizer tops 3Q earnings views, makes progress on COVID shot
Pfizer executives had expected data from their 44,000-person international study would show by Oct. 31 how well it prevents coronavirus infections. Analysts peppered Bourla and other Pfizer executives with so many questions about the study that he repeatedly asked for their patience. It expects revenue of $48.8 billion to $49.5 billion, narrowed from its previous forecast of $48.6 billion to $50.6 billion. Pfizer will receive about $12 billion in return and its shareholders will get roughly one Viatris share for each Pfizer share they own. Pfizer expects to be able to grow revenue at least 6% annually through 2025 as a result of the transformation.
Pfizer: Mid-November earliest it can seek virus vaccine OK
NEW YORK – Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday. Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25. Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.
Pfizer CEO pushes back against Trump claim on vaccine timing
Despite top U.S. federal health officials repeatedly stating that a vaccine is unlikely to be available widely until mid-2021, President Donald Trump has insisted that a vaccine will be ready before Election Day. “I’ve spoken to Pfizer, I’ve spoken to all of the people that you have to speak to, Moderna, Johnson & Johnson, and others. “It’s become very political.”“We’re weeks away from a vaccine,” Trump added. Johnson & Johnson just started the final study of its vaccine last week. ___Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.